Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
ALNYAlnylam Pharmaceuticals(ALNY) Zacks Investment Research·2024-05-02 23:07

Alnylam Pharmaceuticals (ALNY) reported 494.33millioninrevenueforthequarterendedMarch2024,representingayear−over−yearincreaseof54.8494.33 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 54.8%. EPS of -0.16 for the same period compares to -1.40ayearago.Thereportedrevenuerepresentsasurpriseof+17.391.40 a year ago. The reported revenue represents a surprise of +17.39% over the Zacks Consensus Estimate of 421.1 million. With the consensus EPS estimate being -$0.75, the EPS surprise was +78.67%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they c ...